A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2

  • Trends Pharmacol Sci. 2021 May;42(5):313-315. doi: 10.1016/j.tips.2021.02.002.
Marco P Licciardello  1 ,  Paul Workman  2
Affiliations
  • 1. Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • 2. Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK. Electronic address: [email protected].
PMID: 33771354 DOI: 10.1016/j.tips.2021.02.002
Abstract

Casein Kinase 2 (CK2) is highly expressed in Cancer and has been considered a potential therapeutic target. Wells and colleagues developed and characterized the new CK2 Inhibitor SGC-CK2-1. Unexpectedly, this potent and highly selective chemical probe does not show broad antiproliferative activity in Cancer cells.

Keywords
COVID-19; cancer; drug target; neurodegenerative diseases; protein kinase; selective CK2 inhibitor.
Products